|
E-book
Textbook of HemophiliaISBN: 978-1-4051-4386-8
E-book
416 pages
April 2008, Wiley-Blackwell
 Purchase This E-book
This price is valid for United States. Change location to view local pricing and availability.   
|
Foreword.
Part I: Introduction.
1 Overview of Hemostasis.
2 Cellular Processing of Factor VIII and IX.
3 Work-up of a Bleeding Adult.
Part II: HEMOPHILIA A.
4 Molecular Basis of Hemophilia A.
5 Hemophilia A: Role of Factor VIII in Coagulation.
6 Natural History of Inhibitor Development in Children with Severe Hemophilia A Treated with Factor VIII Products.
7 Prophylaxis.
8 Continuous Infusion of Coagulation Products in Hemophilia.
Part III: Inhibitors to Factor VIII.
9 Inhibitors to Factor VIII - Immunology.
10 Inhibitors to Factor VIII - Molecular Basis.
11 Inhibitors to Factor VIII - Epidemiology and Treatment.
12 Inhibitors to Factor VIII - Mid and Moderate Hemophilia.
13 Inhibitors to Factor VIII/IX: Treatment of Inhibitors - Immune Tolerance Induction.
14 Inhibitors of Factor VIII: Treatment of Acute Bleeds.
Part IV: Acquired Hemophilia.
15 Acquired Inhibitors to Factor VIII.
Part V: Hemophilia B.
16 Hemophilia B - Molecular Basis.
17 Inhibitors in Hemophilia B.
18 Treatment Inhibitors in Hemophilia B.
Part VI: Pharmacokinetics of Factors VIII & IX.
19 Pharmacokinetics.
Part VII: Pediatrics.
20 Work-up of a Bleeding Child.
21 Care of the Child with Hemophilia.
22 To Neonate with Hemophilia.
Part VIII: Products Used to Treat Hemophilia.
23 Products Used to Treat Hemophilia: Evolution of Treatment for Hemophilia A and B.
24 Products Used to Treat Hemophilia: Recombinant Products.
25 Products Used to Treat Hemophilia: Plasma-Derived Coagulation Factor Concentrates.
26 Products Used to Treat Hemophilia: Recombinant Factor VIIa.
27 Products Used to Treat Hemophilia: Dosing.
28 Products Used to Treat Hemophilia: Regulation.
Part IX: Muscoskeletal.
29 Joint Replacement.
30 Synovioarthesis in Hemophilia.
31 Pseudotumours in patients with Hemophilia.
32 Radiology.
33 Magnetic Resonance Imaging/ Joint Outcome.
34 Physiotherapy in the Management of Hemophilia.
Part X: Transfusion-Transmitted Disease.
35 Transfusion Transmitted Disease: History of Epidemics (Focus on HIV).
36 Transfusion Transmitted Disease: Hepatitis C Virus Infection and Liver Transplantation.
Part XI: Gene Therapy.
37 Gene Therapy: Introduction and Overview.
38 Gene Therapy for Hemophilia B.
39 Gene Therapy for Hemophilia A.
40 Gene Therapy: Molecular Engineering of Factor VIII and Factor IX.
Part XII: Laboratory.
41 Laboratory Assays in Hemophilia.
42 Standardization of Assays.
Part XIII: Obstetrics & Gynaecology.
43 Obstetrics and Gynecology: Hemophilia.
Part XIV: Von Willebrand Disease.
44 von Willebrand Disease: Molecular Aspects.
45 von Willebrand Disease: Epidemiology.
46 von Willebrand Disease: Biological Diagnosis.
47Classification and Clinical Aspects of von Willebrand Disease.
Part XV: Treatment of Von Willebrand Disease.
48 Treatment of von Willebrand Disease: Desmopressin.
49 Treatment of von Willebrand Disease: Therapeutic Concentrates.
50 Women & Von Willebrand Disease.
Part XVI: Rare Bleeding Disorders.
51 Factor II.
52 Factor V and combined Factor V and VIII Deficiencies.
53 Congenital Factor VII Deficiency.
54 Factor X and Factor X Deficiency.
55 Factor XI Deficiency.
56 Factor XIII.
57 Fibrinogen.
58 Miscellaneous Rare Bleeding Disorders.
XVII: Quality of Life.
59 Quality of Life in Hemophilia.
XVIII: Economics.
60 The Economics of Hemophilia Treatments.
XIX: Comprehensive Care and Delivery of Care.
61 Comprehensive Care and Delivery of Care: The Developed World.
62 The Comprehensive Care and Delivery of Care: The Developing World.
63 Comprehensive Care and Delivery of Care: The Global Perspective.
Index.
How to read this e-book on:
